Key Highlights

  • Biome will launch Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60 in H1 FY27, two-month formats of its two highest-volume products.
  • Biome Daily (30) and Biome Daily Kids (30) are ranked the number one products in their respective categories in Australian pharmacy, according to IQVIA scan data.
  • The new products will be the company's first Australian-made items, manufactured under its onshore agreement with Specialty Probiotics Australia.
  • Both products use microencapsulation technology designed to allow roughly five times more live bacteria to reach the gut compared to uncoated probiotics.

New Products Set for H1 FY27 Launch

Biome Australia Limited (ASX:BIO) has announced two new additions to its Activated Probiotics range, with Biome Daily Probiotic 60 and Biome Daily Kids Probiotic 60 scheduled for launch in the first half of FY27. Both products are two-month, 60-unit formats of the company's two highest-volume lines, which have previously only been available in 30-unit packs. The products will be supplied through Biome's existing community pharmacy wholesalers and its practitioner channel from the first half of FY27.

Product Composition and Clinical Support

Biome Daily Probiotic is a six-strain formulation containing 9 billion live bacteria per capsule, designed for adults and formulated to support digestive and immune health. Its combination of the HEAL9 and 8700:2 strains has been examined in randomised, double-blind, placebo-controlled trials involving more than 1,400 adults, with the studies indicating a reduction in the incidence, duration and severity of common colds. Biome Daily Kids Probiotic is a five-strain, vanilla-flavoured sachet containing 10 billion live bacteria, formulated for children from two years of age to support immune function and maintain gut bacteria during antibiotic use. Both products use Activated Probiotics' microencapsulation technology, which the company states allows approximately five times more live bacteria to survive passage through the stomach and reach the gut compared with uncoated probiotics.

Category Position and Market Data

According to IQVIA pharmacy scan data, Biome Daily is ranked the number one probiotic product in Australian pharmacy by both units and value, while Biome Daily Kids is ranked the number one immune health and kids probiotic product. Both products achieved these rankings in the 30-pack format alone, competing against brands whose core lines are sold in 60 and 90 packs. The company notes that 14 of the top 20 probiotic products in Australian pharmacy, by IQVIA data, are sold in 60 or 90 packs, indicating a portion of the category that Biome's existing 30-pack range has not yet addressed.

Commercial Rationale for the Larger Format

Biome's stated rationale for the new format centres on adherence, noting that probiotics require consistent daily use to deliver their studied benefits, and that running out of product is a common reason patients discontinue use. A two-month Supply is intended to support ongoing use, simplify the recommendation pharmacists and practitioners can make to regular users, and increase transaction value for pharmacy partners. The company has set pricing intended to retain existing customers as they move to the larger pack. Biome has modelled the interaction between the new and existing formats and expects growth in new sales to outpace any substitution away from the 30-pack products, though no Revenue guidance has been provided for the new items.

Supply Chain and Onshore Manufacturing

The new products will be Biome's first to be manufactured in Australia, produced under the company's onshore Manufacturing agreement with Specialty Probiotics Australia. Spreading Demand for the company's two largest-selling lines across an additional SKU each is intended to reduce the risk of stock-outs at the wholesaler or retailer level. Biome also points to efficiency gains from the format, noting that a single carton, label and freight movement will cover two months of supply, which the company states supports its broader objective of improving gross Margin as manufacturing shifts onshore.

Conclusion

Biome Australia's launch of 60-pack versions of its two leading Activated Probiotics products represents an extension into a segment of the pharmacy probiotics category the company has not previously served with its core lines, while also marking its first products manufactured domestically. The company has pointed to the category-leading position of its existing 30-pack products, supporting IQVIA data and a modelled expectation that new sales will exceed any substitution effect, though it has not issued specific revenue guidance for the new items, and actual uptake will only become clear once the products reach pharmacy shelves in the first half of FY27.